$ALDX SEC Filings

Filed On	Filing
29 Sep 2026	8-K: Regulation FD Disclosure; Other Events Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
12 Aug 2026	SCHEDULE 13G
06 Aug 2026	10-Q
30 Jul 2026	8-K: Entry into a Material Definitive Agreement
27 Jul 2026	SCHEDULE 13G/A
15 Jul 2026	8-K: Other Events
11 Jun 2026	Form 4: Miller-Rich Nancy, Director Granted 73,318 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Douglas Richard, Director Granted 92,232 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Phillips Gary M., Director Granted 81,613 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Clark William D, Director Granted 72,323 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Walker Neal, Director Granted 73,318 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Bronstein Ben, Director Granted 80,286 Stock Option (Right to Buy)
11 Jun 2026	Form 4: Deptula-hicks Darlene M, Director Granted 94,313 Stock Option (Right to Buy)
11 Jun 2026	Form 3: Deptula-hicks Darlene M, Director No securities owned
10 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders +1 more
05 Jun 2026	Form 4: Brady Todd C, Director Bought 250,000 shares ($418K)
15 May 2026	SCHEDULE 13G/A
07 May 2026	10-Q
01 May 2026	8-K: Regulation FD Disclosure
27 Apr 2026	ARS

Comments